AP402
HER2‑positive tumors
Phase 1/2Active
Key Facts
About AP Biosciences
AP Biosciences leverages a bispecific antibody platform to advance oncology and ophthalmology candidates through late‑stage clinical trials.
View full company profileHER2‑positive tumors
AP Biosciences leverages a bispecific antibody platform to advance oncology and ophthalmology candidates through late‑stage clinical trials.
View full company profile